8-K: Masimo Reports Strong Q4 and Full-Year 2024 Results, Updates 2025 Guidance Amid Strategic Realignment

Masimo announces positive Q4 and full-year 2024 financial results, driven by healthcare revenue growth, and updates its full-year 2025 guidance, focusing on its core healthcare business.

Summary

• Masimo reported a consolidated revenue of $601 million for Q4 2024, a 9% increase year-over-year on both reported and constant currency bases.
• Healthcare revenue for Q4 2024 was $368 million, reflecting an 8% increase on a reported basis and a 9% increase on a constant currency basis.
• Non-Healthcare revenue for Q4 2024 was $232 million, up 11% on a reported and constant currency basis.
• The non-GAAP gross margin for Q4 2024 was 52.2%, a 240 basis point improvement from the previous year.
• Non-GAAP operating margin for Q4 2024 was 22.4%, a 570 basis point increase year-over-year.
• Non-GAAP EPS for Q4 2024 was $1.80, a 44% increase compared to the prior year.
• For the full year 2024, consolidated revenue reached $2,094 million, a 2% increase on a reported basis and a 3% increase on a constant currency basis.
• Healthcare revenue for the full year 2024 was $1,395 million, a 9% increase on a reported basis and a 10% increase on a constant currency basis.
• Non-Healthcare revenue for the full year 2024 was $699 million, a 10% decrease on a reported basis and a 9% decrease on a constant currency basis.
• The non-GAAP gross margin for the full year 2024 was 53.0%, a 250 basis point improvement from the previous year.
• Non-GAAP operating margin for the full year 2024 was 17.0%, a 170 basis point increase year-over-year.
• Non-GAAP EPS for the full year 2024 was $4.40, a 16% increase compared to the prior year.
• The company provided updated FY 2025 guidance, projecting healthcare revenue between $1,500 million and $1,530 million, representing 8-10% growth on a reported basis and 8-11% growth on a constant currency basis.
• Non-GAAP operating profit for FY 2025 is expected to be between $413 million and $428 million, with an operating margin of approximately 27.5% to 28.0%.
• Non-GAAP earnings per share for FY 2025 are projected to be between $5.10 and $5.40.

Sentiment

Score: 7

Explanation: The sentiment is positive due to strong healthcare revenue growth, improved margins, and a positive outlook for FY 2025. However, the GAAP net loss and decline in non-healthcare revenue temper the overall sentiment.

Positives

• Significant growth in healthcare revenue for both Q4 and full-year 2024.
• Substantial improvement in non-GAAP gross and operating margins.
• Strong growth in non-GAAP EPS.
• Record year for gaining market share through customer contracts, with $432 million in incremental value of new contracts.
• Growth in consumable and service revenue, indicating recurring revenue streams.
• Positive outlook for FY 2025 with projected growth in healthcare revenue and non-GAAP EPS.

Negatives

• Decline in non-healthcare revenue for the full year 2024.
• GAAP net loss per basic share for both Q4 and full-year 2024, primarily due to an impairment of goodwill and intangibles for Sound United.
• Capital equipment and other revenue declined by 20% due to a change in accounting rules (ASC 842).

Risks

• The company's dependence on Masimo SET and Masimo rainbow SET products and technologies for substantially all of its revenue.
• Exposure to competitors' assertions of intellectual property claims.
• The highly competitive nature of the markets in which the company sells its products and technologies.
• The risk that the implementation of the company's international realignment will not continue to produce anticipated operational and financial benefits.
• Potential negative effects or impact on the company's business from new international trade tariffs.
• The guidance does not include any use of proceeds from a sale of Sound United, any potential benefits from new tax policies and any potential impact of new tariffs on our business, which could be material.
• Products sourced from Mexico and potentially subject to U.S. tariffs represent approximately 25% of Masimo's healthcare cost of goods sold.

Future Outlook

Masimo anticipates continued growth in its healthcare segment and expects increased earnings and cash flow in 2025 and beyond as a result of its strategic realignment efforts. The company has provided specific revenue and earnings guidance for FY 2025, focusing on its core healthcare business.

Management Comments

• Katie Szyman, Chief Executive Officer of Masimo, said she is extremely excited about the opportunity to lead such an innovative organization as Masimo refocuses on its core healthcare business.
• Katie Szyman stated that there are numerous unmet clinical needs that Masimo is well-positioned to address and that the company has strong momentum behind it.
• Katie Szyman noted that Masimo's 2024 results clearly demonstrate the strong growth and earnings power of its healthcare business.
• Katie Szyman stated that Masimo had a record year in terms of gaining share through customer contracts.
• Katie Szyman stated that as a result of Masimo's strategic realignment efforts in the fourth quarter, the company expects to see increased earnings and cash flow in 2025 and beyond.

Industry Context

Masimo's focus on its core healthcare business aligns with the broader industry trend of companies streamlining operations to concentrate on high-growth areas. The company's emphasis on innovative monitoring technologies and patient care solutions positions it to capitalize on the increasing demand for advanced healthcare technologies.

Comparison to Industry Standards

• Masimo's growth in healthcare revenue is comparable to other medical device companies focusing on patient monitoring solutions, such as Medtronic and Philips Healthcare.
• The company's non-GAAP gross margin improvement reflects its efforts to optimize operational efficiency, similar to initiatives undertaken by industry peers like Stryker and Boston Scientific.
• Masimo's strategic realignment, including the potential sale of Sound United, mirrors the trend of companies divesting non-core assets to improve profitability, as seen with Johnson & Johnson's separation of its consumer health business.

Legal Proceedings

• The company has been engaged in various legal proceedings against Apple since January 2020, including various proceedings in the federal courts, various proceedings in the U.S. Patent and Trademark Office (the PTO proceedings), and a proceeding in the U.S. International Trade Commission (the ITC proceeding).

Related Party Transactions

• Related party revenue was $50.3 million for the three months ended December 28, 2024, and $114.1 million for the twelve months ended December 28, 2024.

Stakeholder Impact

• Shareholders can expect increased earnings and cash flow in 2025 and beyond.
• Employees may experience changes due to the strategic realignment efforts.
• Customers will benefit from the company's focus on innovative healthcare solutions.
• Suppliers may be affected by changes in the company's supply chain and sourcing strategies.

Next Steps

• The company will hold a conference call on February 25, 2025, to discuss the financial results and outlook.
• Masimo will continue to focus on its core healthcare business and strategic realignment efforts.
• The company will monitor the potential impact of new tariffs on its business.

Key Dates